STUDresearch · Non-peptide
Trevogrumab
Also known as
REGN1033 · anti-GDF8 antibody · anti-myostatin mAb COURAGE · trevogrumab Regeneron
Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.
Non-peptide
Niche talk
Systemic
SubQ trial / not a peptide vial
Growth factors / muscle
Systemic anti-myostatin antibody used in obesity combination trials.
What people say
Trevogrumab is Regeneron’s anti-GDF-8 monoclonal antibody. COURAGE combined it with semaglutide. It is not FLGR-242 or a gray peptide vial.
Doses people talk about
Trial milligrams with semaglutide do not establish a DIY or gym protocol.
How it may feel
No credible direct self-use feel curve was found. Discussion is DEXA press figures, not a weekday pump diary.
COURAGE lower combo200 mg SC
COURAGE lower combo with weekly semaglutide; lean-mass preservation vs semaglutide alone.
COURAGE higher combo400 mg SC
COURAGE higher antibody arm in the same 26-week DEXA table, still with weekly semaglutide.
Half-life & effect duration
- Half-life in the body
- Half-lifeNo settled estimate
- Felt duration people report
- Felt durationNo consistent direct self-use timeline reported
Cycles people discuss
The public clock is a 26-week obesity trial phase, not a copied peptide camp.
Timing
No inspected DIY half-life table. Community talk follows the GLP week, not a 19-day FLGR number.
Stacks
Public screenshots pair it with semaglutide; the triplet adds garetosmab. Kitchen stacks are comparison talk, not a trial arm.
Watch for
Not a peptide shop SKU.
Tap a line to jump into the full notes. Research only — may be wrong.
Timing context & sources
Half-life in the body
No inspected public DIY or consumer half-life table for trevogrumab as a research vial.
COURAGE discusses scheduled antibody plus weekly semaglutide. That calendar is not a measured elimination half-life for a gray-market construct.
Press-release and trial design are not a PK paper for self-administration.
- Regeneron — COURAGE Phase 2 26-week lean-mass results (opens in a new tab)26-week DEXA: semaglutide lean mass −6.5%; + trevogrumab 200 mg −3.3%; 400 mg −3.8%; triplet with garetosmab −2.0%.Obesity combination trial, not healthy-lifter hypertrophy or a research-peptide PK study.
Felt duration people report
No credible direct self-use feel curve was identified.
Discussion is DEXA press figures and comparison to shop follistatin, not hour-by-hour pumps.
No verified n=1 antibody diaries.
- Regeneron — COURAGE Phase 2 26-week lean-mass results (opens in a new tab)26-week DEXA: semaglutide lean mass −6.5%; + trevogrumab 200 mg −3.3%; 400 mg −3.8%; triplet with garetosmab −2.0%.Obesity combination trial, not healthy-lifter hypertrophy or a research-peptide PK study.
What people say
- The tweet: “GLP without melting the gym.” That is lean-mass preservation during weight loss, not 1.5 lb of muscle a week. forum
- No verified peptide-shop n=1 album. Talk is press-release screenshots. forum
- COURAGE 26-week DEXA: Semaglutide alone lean mass about −6.5%; plus trevogrumab about −3.3% (200 mg) or −3.8% (400 mg). Fat loss was larger in combo arms. Obesity trial, not a gym log. trial
- Not a healthy-lifter hypertrophy RCT. trial
Doses people talk about
- No public DIY conversion into a peptide syringe. forum
- COURAGE lower combo: 200 mg trevogrumab with weekly semaglutide 2.4 mg. trial
- COURAGE higher combo: 400 mg trevogrumab with weekly semaglutide 2.4 mg. trial
- Framing: Trial milligrams. Not a research-peptide chart. Not a protocol. trial
How it may feel
- Now: Comparison object for FLGR and “myostatin + GLP” threads. forum
- If a gray vial appears: there is no copied fullness diary for this antibody. forum
- Stop: no community washout lore; almost nobody has a personal history on verified drug. forum
- Trial clock: weeks of titrated semaglutide plus scheduled antibody — not a weekday peptide pump. trial
Cycles people discuss
- Not a 10–30 day FS-344 camp and not a 12–16 week FLGR vendor block. forum
- Trial block: COURAGE weight-loss phase reported at 26 weeks. trial
- Later trial parts exist; do not freeze one press table as a forever schedule. trial
Timing
- Community clock is the GLP week because the antibody is discussed as a combo. forum
- Do not paste 19-day FLGR numbers onto trevogrumab. forum
- No inspected public DIY-vial half-life. This is a mAb, not FLGR albumin lore. trial
More on what it is
- Why people talk about it: 2025–26 COURAGE screenshots — semaglutide plus this antibody kept more lean mass than semaglutide alone. Biohackers use it as the comparison object for FLGR skip-activin talk. forum
- Vs FLGR-242 / FS-344: Those are shop or gene-therapy constructs. This is a named mAb with a public obesity trial. Do not copy peptide milligrams onto it. forum
- Not DIY. Trial/clinic supply. A gray listing with this name is identity risk. forum
- What it is: Regeneron’s monoclonal antibody against GDF-8 (myostatin). People paste the name trevogrumab from COURAGE write-ups. Not a lyophilized peptide SKU. trial
- How it works (plain): The antibody binds circulating myostatin. COURAGE’s activin-A arm is a different antibody (garetosmab). trial
Stacks
- Compared with FLGR / bimagrumab, not stacked in a kitchen. forum
- + Semaglutide is the COURAGE pair people screenshot. trial
- + Garetosmab is the triplet arm (more fat loss, worse discontinuation talk). trial
Storage notes
- Clinic / trial product, not BAC-water culture. forum
- A gray listing with this name is an identity fight. forum
Watch for
- Not a peptide shop SKU. forum
- Lean-mass preservation ≠ hypertrophy for a healthy lifter. forum
- Gray-vial identity. forum
- Combo arms can add antibody-class effects on top of GLP GI. Read the trial table, not a forum SOP. trial
Evidence mix
Mixed trial + community tags
Full: every bullet (trial + community). Use Scan for a faster bro-science read.